Pre‐Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70794 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Rakhi Maiwall und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Liver Failure, Acute, Brain Edema, Continuous Renal Replacement Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Background and Aim An early initiation of continuous renal replacement therapy (CRRT) for ammonia reduction has shown a reduction in deaths due to cerebral edema (CE) in acute liver failure (ALF); however, there are no controlled trials assessing the same.
Methods
We performed an open‐label pilot randomized controlled trial (RCT) on ALF patients with CE. Patients underwent therapeutic plasma‐exchange (PLEX) by centrifugal apheresis after initial resuscitation. Group 1 received CRRT initiation within the first 12 h, while Group 2, CRRT was initiated for PLEX non‐responders. The primary endpoint was 28‐day survival.
Results
Patients aged 28.11 ± 10.10 years, 56.67% viral, 69% hyperacute were randomized. At day 28, 46% died and 11% underwent liver transplant. There were a total of 31 protocol violations, significantly more in group 2 (55.6% vs. 13.3%; p < 0.001). On ITT and piece‐wise exponential regression analysis, pre‐emptive CRRT was associated with a significantly lower hazard of death during the first 7 days (2.2% vs. 17.8% Hazard ratio [HR] 0.12, 95% confidence interval [CI] 0.02–0.96) with comparable survival at 28‐days. Notably, higher 28‐day mortality was observed on PP analysis in group 2 (80% vs. 46%, HR 3.10, 95% CI 1.57–6.12) with a significantly higher reduction in ammonia and improvement in mean arterial pressure and lower number of sessions of TPE. Each hour delay in CRRT was associated with increased mortality (HR 1.01, 1.00–1.02).
Conclusion
A pre‐emptive initiation of CRRT in ALF patients is synergistic to TPE, reduces early deaths by rapid improvement in hemodynamics, ammonia and cerebral edema (NCT04991259).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
- Department of Statistics, Department of Applied Mathematics and Statistics, Pachhunga University College, Mizoram University (A Central University), Aizawl, India.
ORCID-Profile: Shiv Kumar Sarin
Förderung
- Indian Council of Medical Research
Zitieren
APA
Maiwall, R., Bajpai, M., Pasupuleti, S. S. R., Chauhan, N., Prajapati, M., Prasad, M., Agarwal, P., Mathur, R. P., Thomas, S., & Sarin, S. K. (2026). Pre‐Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70794
Vancouver
Maiwall R, Bajpai M, Pasupuleti SSR, Chauhan N, Prajapati M, Prasad M, et al. Pre‐Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70794
BibTeX
@article{Maiwall2026,
author = {Maiwall, Rakhi and Bajpai, Meenu and Pasupuleti, Samba Siva Rao and Chauhan, Neha and Prajapati, Mohit and Prasad, Manya and Agarwal, Prashant and Mathur, Rajendra Prasad and Thomas, Sherin and Sarin, Shiv Kumar},
title = {Pre‐Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70794}
}
EUVIMED